Conditions: Sarcoma, Ewing's
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 65
Healthy volunteers: no

Brief summary:
This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: CP-751,871
Intervention descriptions: intervention 1: Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity

Protocol document: